Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nano Today. 2015 Aug 1;10(4):511–531. doi: 10.1016/j.nantod.2015.06.007

Figure 8.

Figure 8

MSRs as engineered microenvironments for therapeutic vaccination. (a) Diagram illustrating mechanism of MSR in situ self assembly and in vivo function. (b) ELISA analysis of sera OVA-specific IgG2a after immunization with soluble OVA (bolus OVA), soluble GM-CSF, CpG, and OVA (bolus vaccine), soluble OVA with Imject Alum (Alum + OVA), MSRs with OVA (MSR + OVA), or MSR vaccines loaded with GM-CSF, OVA, and CpG (MSR vaccine). Black arrows indicate vaccination days. (c) Survival of naive mice or mice that were prophylactically vaccinated with 150 μg soluble OVA in combination with soluble GM-CSF and CpG (bolus vaccine), MSRs with OVA (MSR + OVA), or MSR vaccines loaded with GM-CSF, CpG, and either 50 μg or 150 μg OVA (MSR vaccine), and challenged with an OVA-expressing murine lymphoma model 10 days later. From [42].